Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 12 points (-0.1%) at 16,435 as of Friday, May 16, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,512 issues advancing vs. 1,401 declining with 184 unchanged. The Health Care sector currently sits down 0.8% versus the S&P 500, which is unchanged. Top gainers within the sector include Intuitive Surgical ( ISRG), up 1.8%, Regeneron Pharmaceuticals ( REGN), up 1.5%, CR Bard ( BCR), up 1.1%, Agilent Technologies ( A), up 1.1% and Thermo Fisher Scientific ( TMO), up 0.9%. On the negative front, top decliners within the sector include NPS Pharmaceuticals ( NPSP), down 4.6%, InterMune ( ITMN), down 4.8%, Isis Pharmaceuticals ( ISIS), down 4.3%, Incyte ( INCY), down 4.2% and Seattle Genetics ( SGEN), down 4.2%. TheStreet would like to highlight 3 stocks pushing the sector higher today: 3. Questcor Pharmaceuticals ( QCOR) is one of the companies pushing the Health Care sector higher today. As of noon trading, Questcor Pharmaceuticals is up $2.21 (2.5%) to $90.64 on light volume. Thus far, 909,703 shares of Questcor Pharmaceuticals exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $88.28-$90.93 after having opened the day at $88.28 as compared to the previous trading day's close of $88.43. Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Questcor Pharmaceuticals has a market cap of $5.3 billion and is part of the drugs industry. Shares are up 62.4% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts who rate Questcor Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Questcor Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Questcor Pharmaceuticals Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.